We observed substantially improved survival with high lifetime prediagnostic RPA in women with a tumor-methylated APC, CCND2, HIN1, or TWIST1 gene promoter compared with active women with unmethylated gene promoters. The gene discussed is CCND2; the disease is neoplasm.